Our Research and Innovation Department had the pleasure of onboarding clinicians to use our device as we begin our strategic alliance with MD Anderson Cancer Center. #EndCancer #NanoTechnology #Oncology

She carved out her own path in finance and it led to ARTIDIS. Please help us congratulate our Chief Financial Officer Janna Eisenbrandt on being featured for International Women's Day. Read more Broadgate London bit.ly/3llmO0L #IWD2023 #EmbracingEquity #WomeninFinance

We would like to congratulate our Clinical Science Lead, Mariam Gachechiladze MD, PhD on co-authoring a scientific article about the immune microenvironment in breast cancer.  Read the full article: lnkd.in/gX29YKKy #BreastCancer #Oncology #Nanotechnology #microenvironment

Join a mission driven organization that has developed the first #nanomechanical technology platform for tissue analytics. The AFM #Biotechnician is a dynamic role that collaborates w/our clients across the US including world-class hospitals. Apply today: bit.ly/40naMTg

Are you ready to help us plan and build infrastructure to deploy and manage predictive models within clinical environments? Join an innovative company that values its employees, we’ve got positions open: artidis.com/careers/ #Oncology #ClinicalTrials #MechanicalBiomarker

Artidis stands for Automated and Reliable Tissue Diagnostics. Our co-founders met at the University of Basel and have been working diligently to reduce health care burdens for patients, clinicians, and hospital administrators. Read full article: bit.ly/42NPqk2 Universität Basel

Basel Area Business & Innovation highlighted ARTIDIS as a promising startup in the medtech space.  Read the full article by Basel Area Business & Innovation here:  bit.ly/3W5Ypu9 Listen to podcast interview with our CEO here: bit.ly/3BGlfiJ #BaselInnovation

On June 7th join our co-founder and Chief Medical Officer, Dr. Marko Loparic for an insightful and thought-provoking panel discussion on the #FutureofHealthcare hosted by #ArcondisGroup. Secure your spot: bit.ly/3MNtCiREvent #BaselInnovation #MedTech #BioTech #Oncology

ARTIDIS made Houston its home base in America because of the forward-thinking #patientcentric institutions at the Texas Medical Center. Special thank you to Dr. Reiser Texas Medical Center Innovation for highlighting our vision for #cancercare Read full article here: tmc.edu/blog/artidisfo…

Alastair Thompson, M.D., chief of the Section of Breast Surgery, is leading a new clinical trial along with breast imaging and pathology colleagues who will investigate a new technology as treatment tool for patients with solid tumors. Dr. Thompson: t.ly/C0OaN

🫁 This week we celebrated #WorldLungCancerDay! As a company dedicated to revolutionizing cancer diagnosis, we are committed to making a difference in the lives of lung cancer patients by spreading knowledge about risk factors, encouraging screenings & right-sizing treatment

Marking a significant achievement in #breastcancer research! The pioneering Nature publication has exceeded 1,000 citations, highlighting its profound influence on breast cancer detection and diagnosis. Read article here lnkd.in/duYV566v #AtomicForceMicroscopy #CancerCare

Fünf #Spin-offs der Universität Basel arbeiten an neuen Krebstherapien: ARTIDIS, Matterhorn Biosciences sowie Cimeio Therapeutics, T3 Pharma und Aukera Therapeutics, die zum Portfolio von BaseLaunch gehören. Mehr erfahren 👇 buff.ly/3seQwYU

We are thrilled to announce our collaboration with the Dan L. Duncan Comprehensive Cancer Center at BCMHouston ! Find out more about the #ANGELstudy: Transforming Breast Cancer Diagnosis and Personalized Therapy Optimization at the Patient's Bedside. artidis.com/artidis-launch…

Learn more about the new ANGEL study and how it can enhance diagnostics and treatments for breast cancer patients. bit.ly/3QLdhNp #BreastCancer #clinicaltrials Alastair Thompson ARTIDIS

We presented our groundbreaking collaborative research with MD Anderson Cancer Center at the #sitc2023 Press Conference, establishing ARTIDIS tissue nanomechanical signature as clinically translatable predictor of response to immunotherapy in combination with low-dose radiation.

It is an honor to join the scientific community at #ESMO23. We presented poster: "First clinical demonstration of the predictive value of tissue Nanomechanical Signature in breast cancer patients in a neoadjuvant therapy setting."

Breaking News from #CICON 2023: The ARTIDIS poster unveiled: “Harnessing Nanomechanical Stroma Remodulation to Overcome Resistance to Immunotherapy.”  Our research focuses on the convergence of Physics and aid to bedside diagnosis in collaboration w/MD Anderson Cancer Center #EndCancer

At ARTIDIS our ongoing mission is to redefine #cancercare. At #SITC2023, our findings highlighted how the ARTIDIS Nanomechanical Signature identifies mechanical barriers in the extracellular matrix hindering T-cell migration and activity against tumor cells.

We are thrilled to announce groundbreaking collaboration with BCMHouston Find out more about the ANGEL Study: Transforming Breast Cancer Diagnosis + Personalized Therapy Optimization at the Patient's Bedside with Over 2,700 Participants. lnkd.in/gH9Qtc_h #breastcancer